This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Mondor's disease

Authoring team

Thrombophlebitis of the superficial veins of the breast or chest wall is known as Mondor's disease. It is an uncommon, self limiting disease (1).

Presentation is with acute pain, frequently following trauma. There will be visible, palpable, tender cord like branching cutaneous grooves (1).

In general, MD is a self-limited, benign disease that resolves in four to eight weeks without requiring any specific treatment (2). However the condition may as long as to six months (1).

Treatment:

  • in some cases, especially in painful MD cases, nonsteroidal anti-inflammatory drugs can relieve the patient of bothersome symptoms (2)
  • if severe local pain, surgical intervention can be considered (2)
  • there is evidence of the effectivenees of anticoagulation in the acute phase of MD (2)
    • with the option of using common medications for superficial thrombophlebitis, such as prophylactic or intermediate doses of low-molecular-weight heparin and subcutaneous administration of fondaparinux (2.5 mg)
      • however, the application of anticoagulation for MD patients remains controversial

Notes:

  • some cases of MD may occur secondary to an underlying disease, such as vasculitis, a hypercoagulative state, or malignancy. Physicians should evaluate the possible presence of an underlying disease, and avoid performing unnecessary invasive tests or treatment (2)

Reference:


Related pages

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.